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ABSTRACT 
Objective: The aim of the present work was to formulate a controlled release dosage form of water soluble drug such as Nizatidine to increase its 
gastric retention in the stomach and consequently, enhance its absorption and improve its bioavailability. 
Methods: Microballoons were prepared by emulsion non solvent evaporation method using ethyl cellulose 7 CP in different ratios. The prepared 
microballoons were evaluated for yield percentage, entrapment efficiency, in vitro buoyancy and in vitro dissolution.  
Results: Results showed that as drug to polymer ratio increased from 1:1 to 1:5 yield percentage, entrapment efficiency, in vitro buoyancy 
increased from 70.4+1.5 to87.2+1.8, from 71.5+2.1 to 90.2+2.6 and from 82.1+3.2 to 93.2+2.6, respectively, while the amount of drug released 
decreased from 88.1+2.1 to 68.9+1.8. When stirring rate increased from 800 rpm to 1600 rpm, the three parameters decreased from 93.2+2.7 to 
81.5, from 96.4+3.5 to 82.6+1.7 and from 97+5.4 to 88.2+4.1, respectively, while the amount released increased from 63.1+2.6 to 73.8+1.2. When 
Span 80 concentrations increased from 0.1% to 2% the three parameters decreased from 95.2+2.6, to 81.6+3.2, from 97.6+1.8 to 82.4+1.8 and from 
97.3+5.2 to 89.1+4.6, respectively, and the amount released percentage increased from 61.2+2.6 to 76.1+1.6. All drug release showed Higuchi 
diffusion models. The increase in the mean Tmax and the decrease in the mean Cmax of microballoons compared to the plain drug indicate a sustained 
release of microballoons and reflects a high improvement in its bioavailability. 
Conclusion: It is evident from this study that microballoons are promising gastric prolonging the delivery system for nizatidine and have good stability. 
Keywords: Microballoons, Gastro retentive system, Nizatidine, Buoyancy. 
 
INTRODUCTION 
The goal of any drug delivery system is to provide a therapeutic 
amount of drug to the proper site in the body to achieve and 
maintain the desired drug concentration [1]. As the numbers of 
drugs have increased new techniques are required to develop orally 
active therapy, thus gastro retentive dosage forms which prolong 
the residence time of drugs in the stomach and improve their 
bioavailability have been developed. Microballoons are gastro 
retentive dosage based on non effervescent approach. They are low 
density system that has sufficient buoyancy to float over the gastric 
contents and remain in the stomach for prolonged period [2]. 
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach 
acid secretion and commonly used in the treatment of peptic ulcer and 
gastro esophageal reflux. Nizatidine has short biological half life (1-2 
h) and susceptible to metabolism by colonic bacteria [3, 4].  
So, the main goal of the present study was to design Nizatidine 
microballoons to increase its gastric residence time in the stomach, 
consequently enhance its bioavailability and increase patient 
compliance. In vitro and in vivo evaluation of the prepared dosage 
forms were performed. The formula which combined excellent 
floating behavior, yield, entrapment and sustained drug release was 
chosen for in vivo investigation in rabbits to determine its 
pharmacokinetics parameters. 
MATERIALS AND METHODS 
Nizatidine was kindly supplied by Saudi Pharmaceutical industries & 
Medical Appliances Corporation (SPIMACO), AL-Qassim city, KSA. 
Ethylcellulose 7 CP was kindly supplied by Egyptian International 
pharmaceutical industrial company, all other solvents and chemicals 
were of analytical grade. 
Preparation of microballoons 
Microballoons were prepared by emulsion non solvent evaporation 
method using mineral oil as the continuous phase. The drug (50 mg) 
and polymer in different proportions from 1:1 to 1:5 drug to polymer 
ratio were weighed and dissolved into a mixture of absolute ethanol 
and methylene chloride (1:1) at room temperature. The above organic 
phase was then emulsified in the mineral oil containing different 
concentrations of Span 80 with vigorous agitation using mechanical 
stirrer (Heidolph PZP-2000, Germany). After 5 min, 60 ml of n-hexane 
(non solvent) were added to the emulsion at a rate of 1 ml/min. 
stirring was maintained until all the organic phase was evaporated. 
Then, microballoons were separated by filtration and washed with 
two portions of n-hexane (100 ml) each. The washed microballoons 
were dried at room temperature over night. 
Characterization of microballoons 
Particle size analysis 
Particle size of microballoons was determined with optical 
microscope (Seizz MC 63 C-Germany) under regular polarized light 
and mean particle size was calculated (n=3) with the help of a 
calibrated oculo meter [5]. 
Yield of microballoons 
The prepared microballoons were collected and weighed. The 
measured weight was divided by total amount of non-volatile 
components, which were used for the preparation of microballoons  
% yield= (actual weight of product/total weight of excipient and 
drug) x100 [6, 7]. 
In vitro buoyancy 
Microballoons (equivalent to 300 mg) were dispersed in 900 ml of 
0.1 N hydrochloric acid solution (pH 1.2) containing Tween 20 (0.02 
w/v %) at 37 oC to simulate gastric fluids. The mixture was stirred 
with a paddle at 50 rpm using dissolution apparatus (Type PTW II, 
Pharma test, Germany) and after 12 hr, the layer of buoyant 
microballoons was pipetted and separated by filtration. The buoyant 
microballoons were dried overnight at room temperature. The 
weight was measured and buoyancy was determined by the weight 
ratio of the buoyant microballoons to the amount dispersed at the 
beginning of experiment [8, 9]. 
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Microballoons were dissolved in a minimum amount of methanol 
and drug was extracted into suitable aqueous media (0.1N 
hydrochloric acid) by evaporating methanol. The solution was 
filtered through what man filter paper, diluted suitably and analyzed 
for drug content spectrophotometrically at 315 nm (UV-
Spectrophotometer Shimadzu UV-1201, Japan) using 0.1N 
hydrochloric acid as a blank [10, 11]. 
In vitro drug release study 
This study was carried out for all batches in dissolution test 
apparatus USP type II. Medium used was 900 ml of 0.1N HCl pH 1.2. 
Microballoons equivalent to 50 mg nizatidine was taken for the 
dissolution studies. The tests were carried out for 12 h at 50 rpm 
and 37±1 °C. Five ml of the aliquot was withdrawn hourly; filtered 
and equal volume of fresh medium was replenished to the 
dissolution vessel to maintain sink condition. The solution was 
analyzed for the drug content spectrophotometrically at 315 nm 
against 0.1N hydrochloric acid as a blank. Three trials were carried 
out for all batches and the average SE (standard error of mean) 
values were calculated [12, 13]. 
Stability study 
Selected formulations were placed in a screw capped glass 
containers and stored at ambient room temperature 25+1 ° C, in 
refrigerator at 4+1 ° C and in oven at 50+1 ° C, for a period of 3 mo. 
The in vitro release amount of nizatidine and other characters was 
determined monthly [14]. 
In vivo study 
HPLC condition 
HPLC (Waters Instrument, Germany) with the reverse phase C18 
column was used. The UV detector was set at 239 nm. The mobile 
phase consisted of 0.01M di hydrogen phosphate adjusted to pH 3.5 
and acetonitrile in a ratio of 63:37 V/V. The eluent was passed 
through the column at a flow rate of 1.5 ml/minute [15]. 
Preparation of standard calibration curve 
Stock solution of nizatidine was prepared at a concentration of 
100µg/ml using the mobile phase. Standard solutions containing 2, 
4, 6, 8, 10, 12, 14, 16 µg were prepared by diluting the stock with the 
mobile phase and analyzed using 20 µl (10 µg/ml) amlodipine as 
internal standard [16]. Standard calibration curve was established in 
plasma by adding 100 µl aliquot of each of the above dilutions to 100 
µl blank plasma. The spiked plasma samples were processed as 
described below. 
Sample preparation 
100 µl of 10 % perchloric acid and 20 µl of internal standard were 
added to 100 µl of the spiked plasma and the unknown plasma was 
shacked vigorously for 1 minute, then 2 ml of diethyl ether was 
added. The mixture was centrifuged at 4000 rpm and 4 ° C. 2 ml of 
supernatant was taken and dried at 40 ° C in vacuum oven. The 
residue then reconstituted in minimal amount of the mobile phase 
and injected into the column [17]. 
Experimental design 
White male rabbits (weighing 1.5-2 kg) were used for the in vivo 
study. Animals were housed in the standardized conditions at the 
animal house of the Faculty of Pharmacy, Zagazig University, Egypt. 
All animals were acclimatized and kept under constant temperature 
(25±2 oC). All animal procedures were performed in accordance to 
the approved protocol for use of experimental animals set by the 
standing committee on animal care of the Faculty of 
Pharmacy, Zagazig University, Egypt. Animals were divided into 
three groups' three rabbits each. The study was designed as a single 
oral dose. All groups received an equivalent of 5 mg nizatidine/kg 
body weight of rabbits (determined by trials). Group 1 received 
nizatidine alone, group 2 received microballoons (1:5, 1200 rpm, 1% 
Span 80) and group 3 was control. One hard gelatin capsule was 
administered to each rabbit through a stomach tube with the aid of 
distilled water. Blood samples (about 1 ml) were withdrawn from 
the sinus orbital into EDTA tubes at 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h 
after each administration. The blood samples were centrifuged 
immediately at 3000 rpm for 10 min and the plasma samples were 
stored at-20±0.5oC for subsequent assay. 
Kinetic analysis of the data 
The data of drug release from microballoons were subjected to 
theoretical analysis to determine the order of kinetic release 
according to the following equations:  
• Zero order kinetic. Ct = Co–Kt. 
• First order kinetic. Log Ct = log Co-Kt/2.303. 
• Diffusion control model. Q/A=2 Co (A/π)½t½ [18]. 
Statistical analysis of the data 
Experimental results were expressed as mean±SE (standard error). 
One-way analysis of variance (ANOVA) was applied to check 
significant differences. Differences were considered to be 
statistically significant at p˂ 0.05 [17, 19, 20]. 
RESULTS AND DISCUSSION 
Good resolved, spherical microballoons with the smooth surface was 
obtained as shown in fig. 1 
 
 
Fig. 1: Photomicrograph of microballoons (1:5, 1% Span80, 
1200 rpm) 
 
Effect of drug: polymer ratio 
As drug to polymer ratio increased from 1:1 to 1:5, the mean 
diameter, yield percentage, percent entrapment and buoyancy 
percentage of the microballoons increased significantly (P˂ 0.05) 
from 230 µm+1.9 to 324 µm+2.6, from 70.4%+1.5 to 87.2%+1.8, 
from 71.5%+2.1 to 90.2%+2.6 and from 82.1+3.2% to 93.2+3.6%, 
respectively (table 1). The diameter of nizatidine microballoons 
increased significantly (p˂ 0.05) with increasing drug to polymer 
ratio. This is in a good agreement with Najmuddin et al., 2010 
(21)who found that the mean particle size of microballoons of 
ketoprofen prepared from ES100 and EL100 increased from 
123.33±15.27 to 192.33±27.5 for ES100 and increased from 
102.33±21.12 to 156.66±27.53 for EL100, when drug to polymer 
ratio increased from 1:1 to 1:3.  
This is also in a good agreement with Gadad et al., 2011 [22], who 
found that the mean particle size of microballoons of captopril 
prepared from ES100 and ethylcellulose increased from 57.66±7.27 
to 93.20±9.63 for ES100 and from 62.46±6.58 to 85.52±6.32 for 
ethylcellulose, when drug to polymer ratio increased from 1:1 to 1:4. 
The increase in particle size with increasing drug to polymer ratio 
could be ascribed to the increase in viscosity of the medium with 
increasing polymer concentration resulting in enhanced interfacial 
tension and diminishing shearing efficiency, this result in formation 
of larger particles [21, 23, 24]. An increase in drug to polymer ratio 
from 1:1 to 1:5, lead to a significant increase in entrapment 
efficiency, yield percentage and floating percentage. These results 
are in a good agreement with that mentioned by Najmuddin et al., 
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2010(21), who prepared microballoons of ketoprofen by emulsion 
solvent diffusion method using ES100, and EL100. They found that, 
the entrapment efficiency, the yield percentage and the floating 
percentage increased from 61.07±0.98 to 81.7±2.02, from 62.4±0.72 
to 89.45±1.5, and from 80.66±2.08 to 91.66±1.52, respectively, with 
increasing the concentration of ES100, and EL100. This is in a good 
agreement with Gadad et al., 2011[22] who prepared floating 
microspheres of captopril using ES100 and found that with 
increasing drug to polymer ratio from1:1 to 1:4, entrapment 
efficiency increased from 76.72±2.57 to 90.9±1.07. Patil et al., 2009 
[25] also found that, with increasing ethylcellulose concentration the 
yield percentage increased from 69.7±0.02 to 76.93±0.02. This could 
be ascribed to the fact that an increase in polymer concentration 
leads to an increase in the viscosity of the medium and 
consequently, the formation of larger particles which leads to an 
increase in the three parameter [11, 21, 25]. 
  
Table 1: Effect of drug to polymer ratio on nizatidine microballoons 
Drug: polymer Mean diameter µm+SE % Yield+SE % Entrapment+SE % Buoyancy+SE 
1:1 230+1.9 70.4+1.5 71.5+2.1 82.1+3.2 
1:2 254+2.3 75.8+1.9 77.1+1.5 86.5+4.1 
1:3 280+1.5 79.5+2.6 82.1+0.9 90.6+3.6 
1:4 300+3.2 84.1+2.6 84.6+1.5 92.2+5.0 
1:5 324+2.6 87.2+1.8 90.2+2.6 93.2+3.6 
Mean+SE, (n=3). 
 
Effect of stirring rate 
As stirring rate increased from 800 rpm to 1600 rpm, the mean 
diameter, yield percentage, percent entrapment and buoyancy 
percentage of the microballoons decreased significantly (P ˂0.05) from 
369 µm+3.4 to 260 µm+2.6, from 93.2%+2.6 to 81.5%+1.9, from 
96.4%+3.5 to 82.6%+1.7 and from 97.0%+4.6 to 88.2%+5.4, 
respectively (Table2). The diameter of microballoons significantly 
decreased (p˂ 0.05) with increasing stirring rate from 800 to 1600 rpm. 
This may be attributed to the fact that the polymer solution under higher 
stirring rates subjected to higher shear force which led to the splitting of 
the polymer solution into smaller droplets [26, 27]. This is in a good 
agreement with Mazumder et al., 2010 [28], who found that as the 
stirring speed of all formulation increased from 800 rpm to 1200 rpm, a 
significant decrease in particle size was observed for ethylcellulose and 
ethylcellulose in combination with ERS100 microballoons. This is also in 
a good agreement with Nath et al., 2010 [29], who found that when the 
stirring speed was increased from 600 to 1000 rpm, particle size of 
salbutamol sulphate loaded ethylcellulose microballoons significantly 
decreased from 397±2.4 to 271±1.8 (p˂ 0.05). 
It was found that increasing the stirring rate lead to a significant 
decrease in the three parameters which could be ascribed to the 
decrease in particle size with the increase in stirring rate [20] and 
this leads to:  
1. A significant reduction in entrapment efficiency as smaller 
particles will entrap less amount of the drug [30]. 
2. A significant reduction in floating percentage as smaller the 
microballoons, the floating ability will be less, while larger the size, 
floating ability will be more [25]. 
3. A significant reduction in yield percentage. 
When the stirring speed was too slow, the diffusion rate of the 
solvent decreased due to the formation of larger droplets. The 
subsequent hardening may decrease the yield of microballoons due 
to their sticking to the vessel and coalescing into aggregates. 
When the stirring speed was too fast, solidification of the polymer 
occurred before the formation of spherical microballoons due to 
higher rate of diffusion e. g., too fast solidification may result in a 
fiber like structure.  
From previous results, it can be concluded that the decrease in 
the yield percentage was mainly due to aggregates at lower 
stirring speed and fiber like structure at higher stirring speed 
[26]. This is in a good agreement with that found by Mazumder 
et al., 2010 [28], who found that when stirring speed was 
increased from 1000 to 1200 rpm, the entrapment efficiency of 
stavudine decreased. 
 
Table 2: Effect of stirring rate on nizatidine microballoons (1:5, 1% Span80) 
Stirring rate(rpm) Mean diameter µm+SE % Yield+SE % Entrapment+SE % Buoyancy+SE 
800 369+3.4 93.2+2.6 96.4+3.5 97.0+4.6 
1200 324+2.6 87.2+1.8 90.2+2.6 93.2+3.6 
1600 260+2.6 81.5+1.9 82.6+1.7 88.2+5.4 
Mean+SE, (n=3). 
 
Effect of span 80 concentration 
As the concentration of Span80 increased from 0.1% to 2%, the 
mean diameter, yield percentage, percent entrapment and buoyancy 
percentage of the microballoons decreased significantly (P˂0.05) 
from 390 µm+5.1 to 290 µm+4.6, from 95.2%+3.6 to 81.6%+2.8, 
from 97.6%+3.4 to 82.4%+2.4 and from 97.3%+5.6 to 89.1%+1.9, 
respectively (Table3). The diameter of microballoons significantly 
decreased as the concentration of Span 80 increased. Increasing the 
surfactant concentration produces smaller and more stable droplets, 
thereby reducing the fusion of smaller droplets to form larger 
droplets or aggregates [26]. This result is in a good agreement with 
Al-Helw et al., 1998 [31] who found that increasing of Span 80 
concentration from 0.1% to 4% leads to a reduction in particle size 
of chitosan microballoons from 390 to 297 µm. Also Mazmuder et al., 
2009 [32], who found that as the concentration of Tween 80 
increased, the mean particle size decreased significantly. This also in 
a good agreement with Jain et al., 2004 [33], who found that the 
mean diameter of albendazole microballoons prepared from ERLP 
significantly decreased from 152.6±2.8 to 132.7±1.3, when 
emulsifier concentration increased from 0.5 to 1.25. An increase in 
Span 80 concentrations from 0.1% to 2%, results in a significant 
decrease in the three parameters.  
The decrease in entrapment efficiency could be attributed to the fact 
that, at low surfactant concentration, the surface of microballoons is 
smooth and intact, while increasing surfactant concentration results 
in a brittle surface, which leads to a drug loss during washing with n-
hexane [34]. The floating ability of microballoons decreased with 
increasing surfactant concentration and this may be due to the easy 
penetration of the simulated gastric fluid solution through the 
porous brittle surface [35]. 
Sabry et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 10, 220-225 
 
223 
Nepal et al., 2007 [26], found that with increasing surfactant 
concentration, the size of microballoons significantly decreased. 
An increase in the surfactant concentration produced smaller and 
more stable droplets, thereby reducing the fusion of smaller 
droplets to form larger droplets or aggregates. Ultimately small 
sized microballoons were generated and this lead to entrapment 
of less amount of the drug, the floating ability decreased and the 
loss of the smallest and lightest particles during filtration 
occurred. This is in a good agreement with Mazmuder et al., 2009 
[32], who found that as the concentration of Tween 80 increased, 
percentage yield and percentage entrapment efficiency decreased 
significantly. 
 
Table 3: Effect of Span80 concentration on nizatidine microballoons characters (1:5, 1200 rpm) 
Span 80 concentration (%)  Mean diameter µm+SE % Yield+SE %Entrapment+SE %Buoyancy+SE 
0.1 390+5.1 95.2+3.6 97.6+3.4 97.3+5.6 
0.6 372+4.1 92.5+2.9 93.1+5.6 95.6+3.8 
1 324+1.6 87.2+1.8 90.2+2.6 93.2+3.6 
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Fig. 2: Effect of drug to polymer ratio on the amount of 
nizatidine released percentage. The data represent the 
mean+SE of three determinations 
 
In vitro drug release study 
Amount of nizatidine released from microballoons was found to be 
decreased significantly (P˂0.05) from 88.1%+1.6 to 68.9%+2.1 after 
12 h when the drug to polymer ratio increased from 1:1 to 1:5. on 
the other hand, the amount of nizatidine released increased from 
63.1%+1.2 to 73.8%+1.8 and from 61.2%+2.6 to 76.1%+1.8, when 
stirring rate increased from 800 to 1600 rpm and Span80 
concentration increased from 0.1% to 2%, respectively (fig. 2, 3 and 
4). Results showed that as drug to polymer ratio increased from 1:1 
to 1:5, the amount of drug released slightly but significantly 
decreased. This is in a good a agreement with that mentioned by 
Najmuddin et al., 2010 [21], who found that the amount of 
ketoprofen released significantly decreased with increasing the 
concentration of either ES100 or EL100 and he ascribed this to the 
fact that the increase in ES100 and EL100 concentration leads to the 
increased density of polymer matrix into the microballoons, which 
result in an increased diffusional path length. This may decrease the 
overall drug release from polymer matrix. Furthermore, smaller 
microballoons are formed at lower polymer concentration and have 
larger surface area exposed to the dissolution medium. The amount 
of nizatidine released increased with increasing stirring rates from 
800 to 1600 rpm. This could be ascribed to the formation of smaller 
particle size microballoons at the higher stirring rates [26]. Smaller 
particles have larger surface area exposed to the dissolution 
medium and hence, higher dissolution rate. This is in a good 
agreement with that mentioned by Khidr et al., 1995 [30], who 
found that an increase of stirring speed from 600 to 1000 during 
preparation of cellulose propionate microballoons enhanced the 
dissolution rate of meclophenamate Na from these microspheres. 
And also with Mazumder et al., 2010 [28], who found that the 
release rate of stavudine increased significantly with the increase of 
stirring speed, this for ethylcellulose or in combination with ERS100 
microballoons. It is clear from the results that, as the concentration 
of the emulsifier increased, the amount of drug released significantly 
increased. This may be explained by two mechanisms; the first is 
that at higher concentration of the emulsifier, the formed 
microballoons were more porous than those made at lower 
concentration [34, 36]. The second mechanism is that the increase in 
surfactant concentration results in the formation of smaller and more 
stable droplets, thereby reducing the fusion of smaller droplets to 
form larger droplets or aggregates [26]. This leads to an increase in 
dissolution rate as the smaller microspheres have larger surface area 
which exposed to the dissolution medium. This is also in a good 
agreement with Mazumder et al., 2009 [32], who found that the 
release rate of chlorpheniramine maleate from etylcellulose and 
cellulose acetate microballoons increased significantly as the 
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Fig. 3: Effect of drug to polymer ratio on the amount of 
nizatidine released percentage. The data represent the 
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Fig. 4: Effect of Span 80 concentration on amount of nizatidine 
released percentage (1:5, 1200 rpm). The data represent the 
mean+SE of three determinations 
 
Stability study 
All selected formulae showed high stability under the stored 
conditions (data not shown). 
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In vivo study 
Fig. 5 shows the chromatogram of rabbit plasma containing 
nizatidine and amlodipine as an internal standard. It can be noticed 
that, a typical and well resolved peaks are obtained for plasma, 
nizatidine and internal standard. The retention times of nizatidine 
and amlodipine are 6 and 3.5 min, respectively. 
The standard calibration curves for nizatidine in rabbit plasma 
ranging from 2-20 µg/ml were prepared by plotting peak area ratio 
against drug concentration. The data for calibration curves are 
shown in fig. 5. It can be observed that, a good linearity is obtained 
with a good correlation coefficient (R) of 0.9942. The mean equation 
obtained for the calibration curve was;  
Y= 0.9792X-0.3794 
Where, Y represents the peak area ratio of nizatidine to amlodipine 
and X represents the concentration of nizatidine in plasma (µg/ml). 
 
 
Fig. 5: Typical HPLC chromatogram of nizatidine and 
amlodipine 
 
The mean plasma concentrations as a function of time for nizatidine 
after oral administration of plain nizatidine and nizatidine 
microballoons are illustrated in fig. 7. From the obtained results, it is 
evident that, there is a significant difference between the mean 
plasma concentrations after oral administration of microballoons at 
all time intervals compared to the plain drug. Also, there was a 
noticeable difference in the Tmax between the plain drug and 
microballoons. 
The mean pharmacokinetic parameters of plain nizatidine and 
nizatidine microballoons represented by the value of Cmax (µg/ml), 
Tmax (hr), t1/2 (hr) and AUC0-24 (µg. hr. ml-1) are summarized in 
table 4. From the obtained data, it is observed that, the absorption 
of plain nizatidine was rapid and reached its peak plasma 
concentration in (1.5±0.08 h), whereas, the mean Tmax for 
microballoons was 3.6±0.12 h. The mean peak plasma 
concentrations (Cmax) were 1.489±0.07 µg/ml for microballoons 
and 2.125±0.11 µg/ml for plain drug. The mean AUC 0-24 was found 
to be 10.375±0.34 µg. hr. ml-1 for microballoons compared to 
10.111±0.51µg. hr. ml-1 for plain drug. From the obtained results, it 
is evident that, there is a significant difference between the mean 
plasma concentrations after oral administration of nizatidine 
microballoons at all time intervals compared to the plain drug. 
Also, there was a noticeable difference in the Tmax between the 
drug and microballoons. The increase in the mean Tmax and the 
decrease in the mean Cmax of microballoons compared to the plain 
drug indicate a sustained release of microballoons and reflect a 
high improvement in its bioavailability. These results are in 
accordance with those of Ofokansi and Adikwu 2007 [37], who 
found that, the bioavailability as well as the time to attain peak 
plasma level for cefuroxime sodium was generally higher from the 
microspheres in comparison with that of the control. 
 
 



















Fig. 6: Standard calibration curve of nizatidine in rabbit plasma 



















Fig. 7: Plasma levels of plain nizatidine and nizatidine 
microballoons. The data represent the mean+SE of three 
determinations
 
Table 4: Pharmacokinetics parameters after oral administration of plain nizatidine and nizatidine microballoons 
Formulae Cmax (µg/ml) Tmax (h) t1/2 (h) AUC0-24 (µg. h. ml-1)  
Plain nizatidine 2.125±0.11 1.5±0.08 3.8±0.05 10.111±0.51 
Nizatidine microballoons 1.489±0.07 3.6±0.12 5.9±0.22 10.375±0.34 
Values are expressed as mean+SE; Cmax, the maximum peak plasma concentrations of nizatidine; Tmax, time of maximum concentration; t1/2, half 
life time; AUC0-24, area under plasma level-time curve over 24 h.  
 
CONCLUSION 
Microballoons promises to be a potential approach for increased 
gastric residence time, enhanced bioavailability and controlled 
delivery of various therapeutic agents. The present study 
reported the development of nizatidine loaded microballoons 
using ethylcellulose polymer. All prepared formulae remained 
buoyant for more than 12 h and released nizatidine in a 
controlled manner over 12 h; thus, they may reduce the 
frequency of dosing thereby, minimize side effects, prolong 
residence time in stomach and increase the efficiency of the 
drug. 
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